Clinical Trial: Alemtuzumab and Rituximab in Aplastic Anemia
Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia
Brief Summary: The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.
Detailed Summary:
Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
Current Primary Outcome: Evaluate efficacy of alemtuzumab and rituximab in aplastic anemia. [ Time Frame: 12 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Measuring the side effects of alemtuzumab and rituximab combination through clinical evaluation [ Time Frame: 12 months ]
Original Secondary Outcome: Same as current
Information By: Hospital Universitario Dr. Jose E. Gonzalez
Dates:
Date Received: July 29, 2011
Date Started: July 2011
Date Completion:
Last Updated: January 3, 2014
Last Verified: January 2014